{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:47:16Z","timestamp":1773967636713,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Extended-spectrum \u03b2-lactamase (ESBL)\u2013producing Enterobacterales are frequent causes of urinary tract infections (UTIs). Severe infections caused by ESBL Enterobacterales are often treated with carbapenems, but optimal treatment for less severe infections such as UTIs is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study included patients admitted to 4 hospitals in an academic healthcare system with an ESBL UTI treated with either a noncarbapenem \u03b2-lactam (NCBL) or a carbapenem for at least 48 hours from 1 April 2014 to 30 April 2018. Those who received an NCBL were compared to those receiving a carbapenem, with a primary outcome of hospital length of stay (LOS) and secondary outcomes of clinical and microbiological response, days until transition to oral therapy, rate of relapsed infection, and rate of secondary infections with a multidrug-resistant organism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Characteristics were similar among patients who received carbapenems (n\u2005=\u2005321) and NCBLs (n\u2005=\u2005171). There was no difference in LOS for the NCBL group compared to the carbapenem group (13 days vs 15 days, P\u2005=\u2005.66). The NCBL group had higher rates of microbiologic eradication (98% vs 92%, P\u2005=\u2005.002), shorter time to transition to oral therapy (5 days vs 9 days, P\u2005&amp;lt;\u2005.001), shorter overall durations of therapy (7 days vs 10 days, P\u2005&amp;lt;\u2005.001), and lower rates of relapsed infections (5% vs 42%, P\u2005=\u2005.0003).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients treated with NCBLs had similar LOS, higher rates of culture clearance, and shorter durations of antibiotic therapy compared to patients treated with carbapenems, suggesting that treatment for ESBL UTIs should not be selected solely based on phenotypic resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac034","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:00:52Z","timestamp":1644876052000},"source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of Noncarbapenem \u03b2-Lactams Compared to Carbapenems for Extended-Spectrum \u03b2-Lactamase\u2013Producing Enterobacterales Urinary Tract Infections"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-7477","authenticated-orcid":false,"given":"Daniel T","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Emory Healthcare, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Emory Healthcare, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K Ashley","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Emory Healthcare, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse T","family":"Jacob","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Elizabeth","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanthia","family":"Wiley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C","family":"Dube","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujit","family":"Suchindran","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"2022021418533062200_CIT0001","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections.","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0002","author":"Centers for Disease Control and Prevention.","journal-title":"Biggest threats and data"},{"key":"2022021418533062200_CIT0003","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2022021418533062200_CIT0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1469-0691.2007.01854.x","article-title":"Evolution of extended-spectrum \u03b2-lactamases by mutation.","volume":"14","author":"Gniadkowski","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2022021418533062200_CIT0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01641355","article-title":"Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.","volume":"11","author":"Knothe","year":"1983","journal-title":"Infection"},{"key":"2022021418533062200_CIT0006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.28.2.302","article-title":"Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.","volume":"28","author":"Kliebe","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021418533062200_CIT0007","first-page":"1975","article-title":"Phenotypic and genotypic methods for detection of extended spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated from ventilator associated pneumonia.","volume":"7","author":"Krishnamurthy","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"2022021418533062200_CIT0008","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections.","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10096-019-03705-w","article-title":"Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriales.","volume":"39","author":"Kim","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022021418533062200_CIT0010","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumonia bloodstream infections and ceftriaxone resistance.","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2022021418533062200_CIT0011","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1086\/342384","article-title":"Has antifungal susceptibility testing come of age?","volume":"35","author":"Rex","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0012","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/jac\/dku143","article-title":"Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.","volume":"69","author":"Zhou","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022021418533062200_CIT0013","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/AAC.12.4.461","article-title":"Beta-lactamase effect on ampicillin treatment of Haemophilus influenzae B bacteremia and meningitis in infant rats.","volume":"12","author":"Moxon","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021418533062200_CIT0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0018578718817933","article-title":"Piperacillin-tazobactam versus carbapenems for the treatment of nonbacteremic urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.","volume":"55","author":"Tullos","year":"2020","journal-title":"Hosp Pharm"},{"key":"2022021418533062200_CIT0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/cid\/ciz1205","article-title":"Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum beta-lactamase-producing organisms?","volume":"71","author":"Sharara","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0016","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem \u03b2-lactams for the treatment of extended-spectrum \u03b2-lactamase infections.","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0017","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime, and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase producing Escherichia coli.","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2022021418533062200_CIT0018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022021418533062200_CIT0019","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae bacteremia.","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2022021418533062200_CIT0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.","volume":"12","author":"Goethaert","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2022021418533062200_CIT0021","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli.","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021418533062200_CIT0022","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021418533062200_CIT0023","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.","volume":"54","author":"Rodriguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae.","volume":"64","author":"Kang","year":"2012","journal-title":"J Infect"},{"key":"2022021418533062200_CIT0026","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022021418533062200_CIT0027","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia.","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022021418533062200_CIT0028","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae.","volume":"60","author":"Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021418533062200_CIT0029","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"2022021418533062200_CIT0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMra041359","article-title":"The new \u03b2-lactamases.","volume":"352","author":"Jacoby","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofac034\/42531801\/ofac034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/3\/ofac034\/42531801\/ofac034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:01:13Z","timestamp":1644876073000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac034\/6528475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac034","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2022,2,14]]},"article-number":"ofac034"}}